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Extended spectrum beta lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae are known to cause 
nosocomial outbreaks which emerged as one of the world’s extreme health threats in past two decades. In this context, the 
present study was aimed to isolate multi drug resistant E. coli and K. pneumoniae and evaluated the ESBL production. The 
samples were collected from district Govt. hospital, Ariyalur, Tamil Nadu, India in the period of September 2014 to 
September 2015 and a total of 1400 nosocomial isolates were isolated. All the isolates were subjected to antibiotic 
susceptibility testing by Kirby–Bauer disc diffusion method. E. coli (n = 160) had shown high antibiotic resistance pattern to 
Amikacin, Ceftazidime and Nalidixic acid while K. pneumoniae (n = 110) had shown high antibiotic resistance pattern to 
Ceftazidime and Nalidixic acid. Based on the phenotypic confirmatory test, 163 (60.4%) isolates (n = 89, 
 E. coli and n = 74, K. pneumoniae) were ESBL producer. ESBL-positive isolates were screened for the presence of ESBL 
encoding blaTEM, blaSHV, blaCTX‐M-1, blaNDM-1, blaIMP1 and blaGES resistance genes by multiplex polymerase chain reaction 
(mPCR).  Among the ESBL producing genes, blaCTX-M-1 was the highest (90.8%) prevalence followed by blaTEM (77.3%), 
blaGES (19%) and blaNDM-1 (3.1%) alone or together.  The present study concluded that the highest prevalence of ESBL 
producing MDR E. coli and K. pneumoniae with multiple resistance genes demand for new therapeutic options. 
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Introduction  
Extended spectrum beta lactamase (ESBL) 
producing Gram negative bacteria have rapidly spread 
worldwide in last two decades which remain a  
public health concern1. Nowadays, nosocomial  
infections caused by multidrug resistant (MDR) 
enterobacteriaceae and its associated diseases 
significantly increased mortality and morbidity2-3. 
However, ESBL producing MDR Escherichia coli 
and Klebsiella pneumoniae infections have emerged 
as one of the world's greatest health threats because of 
resistance to the third generation cephalosporin and 
has become a major problem presently4. 
ESBLs are plasmid mediated bacterial enzymes that 
confer resistance to utmost beta-lactam antibiotics, 
including third and fourth-generation cephalosporins 
except cephamycins and carbapenems. These 
enzymes generate serious therapeutic challenge to 
clinicians due to its limited therapeutic options  
which are mainly caused by MDR E. coli and K. 
pneumoniae5-6. The ESBL-encoding genes are 
plasmid encoded mostly TEM-, SHV-, and CTX-M-
type enzymes and are commonly produced by E. coli 
and K. pneumoniae7-8. During 1990s, ESBL-
producing organisms were labeled mainly as members 
of the TEM- and SHV-β-lactamase families in E. coli 
and K. pneumoniae causing nosocomial outbreaks. 
The rapid spread of highly virulent ESBL producing 
bacteria, particularly E. coli and K. pneumoniae to 
Asia and all over the world is now an important alarm 
for the development of new therapies against such 
infection9. The emergence of ESBL producing MDR 
bacteria, particularly E. coli and K. pneumoniae are 
now important alarm for the development of therapies 
against bacterial infection. ESBLs are more prevalent 
in E. coli and K. pneumoniae than any other Gram 
negative bacterial species and the occurrence of 
infections caused by ESBL producing strains have 
been widely reported10.  
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Several risk factors that are associated with these 
ESBL producing E. coli and K. pneumoniae  microbial 
infection include advanced age and patients’ previous 
comorbidities (such as neoplasia, renal failure, 
immunosuppression, etc.), long hospital stay, use of 
invasive devices (urinary catheters, venous catheters, 
endotracheal tubes) and previous therapy with wide 
spectrum antibiotics9,11-12. However, the genomic level 
studies elucidating the prevalence of ESBL producing 
MDR E. coli and K. pneumoniae in hospitalized patients 
in Tamilnadu is scanty. Hence, the present study was 
aimed to determine the prevalence of ESBL producing 
MDR E. coli and K. pnuemoniae in Govt. hospital, 
Ariyalur, Tamil Nadu, India. 
 
Materials and Methods 
 
Sample and Data Collection 
The study was executed for a period of 12 months 
(September 2014 to September 2015) at Ariyalur 
district Govt. hospital, Tamil Nadu. A total of 1400 
clinical samples comprising of feces (120), sputum 
(105), nasal swabs (118), cerebrospinal fluid (102), 
urine (324), pus (135), wound swab (205), 
endotracheal aspirate (185) and cervical swab (106) 
were collected from long stay patients, ICU, surgical 
wards and neonatal wards. All the clinical specimens 
were quickly transported to the laboratory for 
isolation of microbial pathogen. Using standard 
methods described by Al-Amin et al13 the pathogenic 
E. coli and K. pneumoniae were selectively isolated 
and identified from the clinical specimens. 
 
Antibiotic Susceptibility Testing 
Antimicrobial susceptibility test was performed 
using the Kirby-Bauer disk diffusion method as per 
the Clinical and Laboratory Standards Institute 
(CLSI) guidelines14 with the following set of 
antibiotics (Hi-media, Mumbai): amikacin (30 μg), 
gentamicin (10 μg), cotrimoxazole (25 μg), 
tetracycline (30 μg), ceftazidime (30 μg), cefotaxime 
(30 μg), cefoperazone (75 μg), ciprofloxacin (5 μg), 
ofloxacin (5 μg), piperacillin/tazobactam (100/10 μg), 
imipenem (30 μg) and nalidixic acid (30 μg). All the 
antibiotic discs (Hi-Media, Mumbai) were 
impregnated onto bacterium inoculated, dried surface 
of a 150 mm Muller Hinton agar plate, and incubated 
at 37oC for 24 hours. After the incubation the zone of 
bacterial clearance was measured and the sensitivity 
was compared using Hi-Media standards. 
 
ESBL Production Assay  
All E. coli and K. pneumoniae isolates from the 
clinical specimens were tested for ESBLs production. 
The ESBL producing MDR strains were determined 
by the phenotypic confirmatory test according to the 
Clinical and Laboratory Standards Institute (CLSI)14. 
A confirmatory test for ESBL-production was 
performed using the double-disk (combined-disk) 
method. The zones of inhibition of each isolate were 
tested on Mueller-Hinton agar plates against the disks 
containing 30 μg of ceftazidime only and in a 
combination with 10 μg of clavulanic acid 
respectively. As per the standards the ESBL 
phenotypes were classified, briefly, the zone of 
inhibition produced off by combination disc was  
more than 5 mm larger than that produced by  
the corresponding antimicrobial disc without  
clavulanic acid.  
 
DNA Extraction 
All the positive ESBL isolates (n = 163) were used 
for genomic DNA extraction. Genomic DNA from  
the bacterial isolates was extracted by modified  
STE (Sucrose Tris EDTA) method with slight 
modification15.  
 
Multiplex Polymerase Chain Reaction (mPCR) 
All mPCR reactions were performed in a 25 μl 
volume containing 2.5 µl of 10X PCR buffer,  
2.0 µl of 1.24 mM dNTPs, 1.0 µl of 10.0 pmol each 
primer, 0.2 µl of 5 U Taq polymerase and 3.0 µl of 
template DNA. The nuclease free water was used to 
bring the reaction mixture to 25 µl. The target 
genes of blaTEM16, blaSHV16, blaCTX‐M-116, blaIMP117, 
blaNDM-118 and blaGES19, primer sequences, PCR 
conditions and amplified product sizes are given  
in the Table 1. The reference strain of  
K. pneumoniae ATCC 1705 was used as a positive 
control and the same reaction mixture except  
the DNA template was considered as negative 
control. The amplified PCR products were 
separated on a 0.9% agarose gel, stained with 
ethidium bromide (0.5 µg/ml) and the gel images 
were taken using a gel documentation system  
(UVI tech, Cambridge)20. 
 
Results 
A total of 1400 clinical samples were isolated from 
Ariyalur district Govt. hospital, Tamil Nadu and  
out of 1400 clinical samples, 376 Gram negative 
bacteria were isolated. They were 160 E. coli 
(42.55%), 110 K. pneumoniae (29.26%), 50 
Pseudomonas aeruginosa (13.3%), 34 Enterbacter 
aerogenes (9.04%), 15 Acinetobacter baumannii 
(3.99 % and 7 Proteus sp. (1.86%). Around 55.62% 
(n = 89) E. coli and 67.27% (n = 74) K. pneumoniae 
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isolates showed ESBL positive (Table 2). The 
susceptibility tests were carried out by disc diffusion 
method. ESBL producing E. coli isolates showed high 
resistance to amikacin, ceftazidime and nalidixic acid 
(100%) whereas ESBL producing K. pneumoniae 
isolates were highly resistant to ceftazidime and 
nalidixic acid (100%). The antibiotic resistance 
pattern of E. coli and K. pneumoniae were shown  
in the Table 3. 
The phenotypic confirmatory test of ESBL 
producers were analysed for all the isolates. The 
production of ESBL was confirmed by phenotypic 
confirmatory test and the distribution of 270 isolates, 
163 (60.4%) isolates were observed ESBL positive in 
which E. coli isolates were in peak followed by  
K. pneumoniae (Table 3). The remaining 39.63% (107 
of 270) isolates were non ESBL producers. Among 
the 270 isolates, 160 (59.25%) showed E. coli, of 
which 56% were from male and 44% from female 
patients. Although, 110 (40.74%) showed K. 
pneumoniae, of which 48% were from male and 52% 
from female patients (Table 4). 
All the 163 isolates were subjected to genotypic 
detection of ESBL encoding resistant genes by mPCR 
analysis and the results are presented in Figure 1. 
Among 163 isolates, the highest percentage of ESBL 
production was seen in E. coli (n = 89) followed by K. 
pneumoniae (n = 74). Among the 163 isolates, blaCTX-
M-1 gene was more prevalent in 90.8% (148 out of 
163) followed by blaTEM gene 77.3% (126 out of 163), 
blaGES 19% (31 out of 163) and blaNDM-1 3.1% (5 out 
of 163).  
 
Discussion 
Extended spectrum beta lactamase producing 
Gram-negative bacteria, particularly E. coli and K. 
pneumoniae, are now widespread nosocomial 
pathogens which cause a variety of infections such as 
septicemia, urinary tract infection, hospital-acquired 
pneumonia, intra-abdominal abscess, brain abscess, 
and device-related infections9. Kumar et al21 reported 
that in India, the incidence of ESBL mediated 
resistance was observed among 60 – 68% of clinical 
pathogens that were isolated from major hospitals. 
 
Table 1 — List of PCR primer pairs sequence used for the detection of antibiotic resistance genes 
Primer direction Locus Primer sequence Amplicon 
(bp) 
PCR condition Reference 
Temp (°C) T (sec)  
blaTEM(+) TEM GAGTATTCAACATTTCCGTGTC 800 56 30 16 
blaTEM(-) TAATCAGTGAGGCACCTATCTC 
blaSHV (+) SHV ATGCGTTATATTCGCCTGTG 867 52 60 16 
blaSHV (-)   TTAGCGTTGCCAGTGCTC 
blaCTX-M-1(+) CTX-M-1 GCGTGATACCACTTCACCTC 300 50 60 16 
blaCTX-M-1 (-)   TGAAGTAAGTGACCAGAATC 
blaIMP1 (+) IMP1 GGCAGTCGCCCTAAAACAAA 737 51 60 17 
blaIMP1 (-) TAGTTACTTGGCTGTGATGG 
blaNDM-1 (+) NDM-1 GGTGCATGCCCGGTGAAATC 660 61 60 18 
blaNDM-1 (-) ATGCTGGCCTTGGGGAACG 
blaGES (+) GES GTTTTGCAATGTGCTCAACG 371 48 60 19 
blaGES (-) TGCCATAGCAATAGGCGTAG 
 
Table 2 — Distribution of ESBL producing MDR E. coli and K. pneumoniae 
Specimen Distribution of nosocomial isolates  ESBL producing MDR strains 
E. coli K. pneumoniae E. coli K. pneumoniae 
Feces (n = 120) 17 (14.17%) 5 (4.17%) 10 (8.33%) 3 (2.5%) 
Sputum (n = 105) 18 (17.14%) 6 (5.71%) 12 (8.0%) 4 (3.81%) 
Nasal swabs (n = 118) 17 (14.41%) 15 (12.7% 8 (6.78%) 10 (8.47%) 
Cerebrospinal fluid (n = 102) 11 (10.78%) 12 (11.76%) 3 (2.94%) 2 (1.96%) 
Urine (n = 324) 38 (11.73%) 20 (6.17%) 14 (4.32%) 12 (3.7%) 
Pus (n = 135) 12 (8.89%) 14 (10.37%) 7 (5.19%) 10 (7.41%) 
Wound swab (n = 205) 25 (12.2%) 13 (6.34%) 20 (9.76%) 12 (5.85%) 
Endotracheal aspirate (n = 185) 12 (6.5%) 10 (5.41%) 8 (4.32%) 9 (4.86%) 
Cervical swab (n = 106) 10 (9.43%) 15 (14.15%) 7 (6.6%) 12 (11.32%) 
Total (n = 1400) 160 (11.42%) 110 (7.86%) 89 (6.36%) 74 (5.29%) 
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In the present study, E. coli (59.25%) is the most 
common cause of nosocomial infections followed by 
K. pneumoniae (47.74%). Because, E. coli usually 
present in the human intestine and it is an 
opportunistic pathogen to become resistant when host 
factors that alter susceptibility to infection22. 
Furthermore, ESBL production was found to be 163 
out of 270 (60.4%). The similar study conducted in 
India by Akram et al23 reported that the E. coli 
showed high antibiotic resistance pattern followed by 
K. pneumoniae. Among 270 isolates, ESBL producing 
MDR E. coli and K. pneumoniae were mostly isolated 
from urine followed by ICU and surgical ward. 
Chauhan24 confirmed that maximum number of ESBL 
isolates were obtained from urine sample (74.0%) 
followed by pus sample (14.6%), surgery ward 
(21.9%) and ICUs (17.6%), respectively. Pathak and 
Pokharel25 reported the prevalence of ESBL 
producing isolates varies geographically and the 
prevalence of ESBL is clearly increasing gradually. In 
many parts of world, 10-40% of strains of  
K. pneumoniae and E. coli express ESBLs. Agrawal 
et al26 had reported the prevalence of the ESBL 
producers to be 6% to 87% in his previous studies 
from India.  
In the present study, molecular detection and 
characterization of ESBL producing blaCTXM-1 gene 
was more prevalent in 90.8% (148 out of 163) 
followed by blaTEM gene 77.3% (126 out of 163), 
blaGES 19% (31 out of 163) and blaNDM-1 3.1% (5 out 
of 163) respectively. Molecular detection and 
characterization of ESBL producing MDR E. coli 
and K. pneumoniae pathogens confirmed that 
blaCTX-M-1 gene was more prevalent among common 
ESBL genotypes and this resistant gene is found to 
be more dissemination among ESBL producing 
Enterobacteriaceae. The mechanism of ESBL gene 
transfer is successively transmitted to the next 
progeny via vertical gene transfer or other bacteria 
through horizontal gene transfer process, making 
their treatment more difficult27. Canton  et al28 
confirmed the mobilization of blaCTX-M-1 genes via 
transposons onto plasmids has guided to the 
successful dissemination and adaptation among the 
bacterial clones. The blaGES and blaNDM-1 are also 
plasmid encoded genes however it was found to be 
low (19% and 3.1%, respectively) in our study, 
might be the recent emergence of such genes in the 
 
Table 3 — The antibiotic resistance pattern of E. coli
K. pneumoniae 
Antibiotics Drug resistant pathogens (%) 
E. coli (n = 160) K. pneumoniae (n = 110) 
Amikacin 160 (100) 72 (65.45) 
Gentamicin 154 (96.25) 50 (54.54) 
Tetracycline 158 (98.6) 44 (30.9) 
Ceftazidime 160 (100) 110 (100) 
Ciprofloxacin 68 (42.5) 93 (84.54) 
Nalidixic acid 160 (100) 110 (100) 
Ofloxacin 135 (84.4) 31 (28.2) 
Co-trimaxazole 145 (90.6) 86 (78.2) 
Doxycycline 
hydrochloride 151 (94.4) 91 (82.73) 
Piperacillin/ 
tazobactam 87 (54.4) 38 (34.54) 
Impinenem 30 (18.75) 21 (19.1) 
Cefoperazone 126 (78.75) 107 (97.3) 
 
Table 4 — Demographic characteristics of the patient population 
of ESBL producing MDR E. coli and K. pneumoniae 
Age 
group 
Distribution of 
nosocomial 
isolates (E. coli) 
Total Distribution of 
nosocomial isolates 
(K.  pneumoniae) 
Total 
(years ) Male Female Male Female 
<10 16 30 46 10 14 34 
10-60 34 30 64 20 24 44 
> 60 14 36 50 17 15 32 
Total 64 96 160 47 53 110 
 
 
 
 
Fig. 1 — Agarose gel electrophoresis of multiplex polymerase 
chain reaction (mPCR) products. A. mPCR analysis for 
identification of blaCTX-M-1 gene resistant strains. Lane M –DNA 
marker (100 bp), Lane 1: K. pneumoniae - Reference strain 
(positive control); Lane 2: other tested strain, Lane 3-6: E. coli
and K. pneumoniae isolates, Lane 7: Nuclease free water 
(negative control); B. mPCR analysis for identification of blaTEM
gene resistant strains. Lane 1: K. pneumoniae - Reference strain 
(positive control); Lane 2, 3, 4, 5: E. coli and K. pneumoniae
isolates, Lane M - DNA marker (100 bp), Lane 6: Nuclease free 
water (negative control); C. mPCR analysis for identification of 
blaGes gene resistant strains. Lane 1: K. pneumoniae - Reference 
strain (positive control), Lane 2-5: E. coli and K. pneumoniae
isolates, Lane M –DNA marker (100 bp), Lane 6: Nuclease free 
water (negative control); D. mPCR analysis for identification of 
blaNDM-1 gene resistant strains. Lane 1: K. pneumoniae - Reference 
strain (positive control); Lane 2-5: E. coli and K. pneumoniae
isolates, Lane M - DNA marker (100 bp); Lane 6: Nuclease free 
water (negative control). 
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hospital environment. Apart from antibiotic 
resistance, ESBL-plasmid-carriage may also 
enhance adaptive virulence of ESBL-producing  
E. coli29. Similar study has done by Sima et al30 
reported that ESBL-producing strains revealed  
that blaCTX-M-1 genes were the most frequent  
ESBL types (74%), followed by blaTEM (67%) and  
blaSHV (45%).  
In the present study, the age group of 0-10 were 
found to be more susceptible to ESBL (Table 4) 
and the prevalence of MDR E. coli and  
K. pneumoniae were observed that more organisms 
were isolated from female compare to men. This 
may be due to low immunity. Similar study has 
done by Schoevaerdts et al31 reported that a  
two-thirds of the patients carrying ESBLs were 
elderly adults aged over 65 years and who 
presented a large variety of co-morbidities.   
From our findings, the abundance of the ESBL 
producers was high because of less hygiene, poor 
knowledge in disease management or treatment, 
inadequate facilities for diagnosis those MDR 
pathogens. In this context, some guidelines were 
reported by Ikeda et al32 that propose general 
standard precautions for the infection at all medical 
facilities, particularly infection by MDR organisms, 
including ESBL-producing bacteria.  
 
Conclusion 
The present study highlight the prevalence of third 
generation cephalosporins resistant nosocomial 
isolates with multiple ESBL gens which plays an 
important role in conferring resistance of E. coli and 
K. pneumoniae strains to β-lactam antibiotics. The 
frequency of blaCTX-M-1, blaTEM, blaGES, and blaNDM-1 
genes in the nosocomial isolates highlights an urgent 
need to develop valuable strategies for the prevention 
and control of diseases.  
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